71690-89-6

Usage

Uses

Used in Organic Synthesis:
CYCLOBUTANECARBOXAMIDINE HYDROCHLORIDE is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the creation of new compounds and materials.
Used in Pharmaceutical Research:
In pharmaceutical research, CYCLOBUTANECARBOXAMIDINE HYDROCHLORIDE is utilized as a compound of interest for its potential to develop into new drugs, particularly due to its antiparasitic and antifungal properties, which have shown promising results in in vitro experiments.
Used in Drug Development:
CYCLOBUTANECARBOXAMIDINE HYDROCHLORIDE is considered in drug development for its anesthetic and analgesic properties, making it a potential candidate for the creation of medications aimed at pain relief and anesthesia.
Further research is necessary to fully understand the biological effects and potential applications of CYCLOBUTANECARBOXAMIDINE HYDROCHLORIDE, ensuring its safe and effective use across different industries.

InChI:InChI=1/C5H10N2/c6-5(7)4-2-1-3-4/h4H,1-3H2,(H3,6,7)

Upstream product

• 4426-11-3 cyclobutanecarbonitrile 

Relevant academic research and scientific papers

DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS

Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H- imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; The identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor

Heteroalicyclic carboxamidines were synthesised and evaluated as inhibitors of nitric oxide synthases. (2R)-2-Pyrrolidinecarboxamidine, in particular, was shown to be a highly potent in vitro (IC50 = 0.12 μM) and selective iNOS inhibitor (>100-fold vs both eNOS and nNOS), with probable binding to the key anchoring glutamate residue and co-ordination to the haem iron.

NOVEL COMPOUNDS

The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the ph

11B-HSD1 inhibitors for the treatment of diabetes

Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.